drugset
drugset / Trial / NCT02564744

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

NCT02564744 ↗

Phase 2 Completed 100 enrolled Debiopharm International SA
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.

Timeline

Start
2016-06-05
Primary completion
2021-01-13
Completion
2021-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject NARATUXIMAB EMTANSINE Unknown 0.2 mg/kg Intravenous
Subject NARATUXIMAB EMTANSINE Unknown 0.7 mg/kg Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma